{"id":2110,"date":"2026-09-08T07:06:00","date_gmt":"2026-09-07T22:06:00","guid":{"rendered":"http:\/\/project-sbi.local\/ir-news\/sbi%ec%9d%b8%eb%b2%a0-%ed%8f%ac%ed%8a%b8%ed%8f%b4%eb%a6%ac%ec%98%a4-%ec%95%84%eb%a6%84%ed%85%8c%eb%9d%bc%ed%93%a8%ed%8b%b1%ec%8a%a4-%ec%85%80%ed%8a%b8%eb%a6%ac%ec%98%a8%ea%b3%bc-%ec%98%a4%eb%a0%89\/"},"modified":"2026-10-22T17:01:31","modified_gmt":"2026-10-22T08:01:31","slug":"sbi-investment-portfolio-company-arum-therapeutics-co-develops-orexin-drug-with-","status":"publish","type":"ir","link":"https:\/\/sbi13.dayworks.kr\/en\/ir-news\/sbi-investment-portfolio-company-arum-therapeutics-co-develops-orexin-drug-with-\/","title":{"rendered":"SBI Investment Portfolio Company Arum Therapeutics Co-Develops Orexin Drug with Celltrion\u2026 Targeting Phase 1 Trial in the Second Half of Next Year"},"content":{"rendered":"<ul>\n<li>Arum Therapeutics, an SBI Investment portfolio company and biotech venture, is co-developing with Celltrion a new drug that acts as an agonist of OX2R (orexin 2 receptor), which is involved in regulating sleep and wakefulness.<\/li>\n<li>In January, the two companies jointly filed an international patent application for \u2018novel orexin 2 receptor agonists and uses thereof\u2019 (with the international application filed in July last year). The program is currently in the preclinical stage, and they are preparing to enter a Phase 1 trial in the second half of next year.<\/li>\n<li>Although its orexin-class program trails global leaders such as Takeda Pharmaceutical and Eli Lilly in development stage, Arum Therapeutics plans to accelerate further development through its collaboration with Celltrion.<\/li>\n<\/ul>\n<p>The full article is available at the link below.<\/p>\n<p><a href=\"https:\/\/www.sentv.co.kr\/article\/view\/sentv202609040194\" target=\"_blank\" rel=\"noopener\">https:\/\/www.sentv.co.kr\/article\/view\/sentv202609040194<\/a><\/p>\n","protected":false},"featured_media":0,"template":"","ir_type":[40],"class_list":["post-2110","ir","type-ir","status-publish","hentry","ir_type-news-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/sbi13.dayworks.kr\/en\/wp-json\/wp\/v2\/ir\/2110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sbi13.dayworks.kr\/en\/wp-json\/wp\/v2\/ir"}],"about":[{"href":"https:\/\/sbi13.dayworks.kr\/en\/wp-json\/wp\/v2\/types\/ir"}],"wp:attachment":[{"href":"https:\/\/sbi13.dayworks.kr\/en\/wp-json\/wp\/v2\/media?parent=2110"}],"wp:term":[{"taxonomy":"ir_type","embeddable":true,"href":"https:\/\/sbi13.dayworks.kr\/en\/wp-json\/wp\/v2\/ir_type?post=2110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}